» Articles » PMID: 18682601

IL-4 Protein Expression and Basal Activation of Erk in Vivo in Follicular Lymphoma

Overview
Journal Blood
Publisher Elsevier
Specialty Hematology
Date 2008 Aug 7
PMID 18682601
Citations 30
Authors
Affiliations
Soon will be listed here.
Abstract

Follicular lymphoma (FL) is characterized by constitutive expression of Bcl-2 as a consequence of t(14;18). Evidence suggests factors in the lymph node microenvironment, related to intratumoral T cells, macrophages, and dendritic cells, play a role in the disease process. We generated proteomic cytokine profiles of FL (N = 50) and follicular hyperplasia (FH; N = 23). A total of 10 cytokines were assayed using ultrasensitive multiplex enzyme-linked immunosorbent assays: IL-1beta, IL-2, IL-4, IL-5, IL-8, IL-10, IL-13, IL-12p70, tumor necrosis factor-alpha, and interferon-gamma. Each cytokine showed overall lower protein concentrations in FL, with the exception of IL-4, which was nearly 5 times higher in FL than FH (P = .005). Using reverse-phase protein microarrays (RPMAs), we evaluated the activation state of several intracellular signaling proteins downstream of cytokine receptors. Basal Erk phosphorylation was approximately 4 times greater in FL than FH (P < .001), with similar findings for Mek; Stat-6 showed weak basal phosphorylation that was approximately twice as high in FL than in FH (P = .012). In conclusion, the FL microenvironment contains increased levels of IL-4, with prominent tumor basal phosphorylation of Erk. These findings suggest IL-4, Erk, and possibly Stat-6 may play a role in the biology of FL and may serve as targets for future therapies.

Citing Articles

STAT6 mutations compensate for CREBBP mutations and hyperactivate IL4/STAT6/RRAGD/mTOR signaling in follicular lymphoma.

Shao Q, Bedi K, Malek I, Shedden K, Malek S Leukemia. 2025; .

PMID: 39910284 DOI: 10.1038/s41375-025-02525-6.


NK Cells in the Lymph Nodes and Their Role in Anti-Tumour Immunity.

Graham L, Khakoo S, Blunt M Biomedicines. 2024; 12(8).

PMID: 39200132 PMC: 11351147. DOI: 10.3390/biomedicines12081667.


Advances in the multi-omics landscape of follicular lymphoma.

Xu T, Zheng Z, Zhao W Int J Biol Sci. 2023; 19(6):1955-1967.

PMID: 37063433 PMC: 10092758. DOI: 10.7150/ijbs.80401.


Insights into the tumor microenvironment of B cell lymphoma.

Ng W, Ansell S, Mondello P J Exp Clin Cancer Res. 2022; 41(1):362.

PMID: 36578079 PMC: 9798587. DOI: 10.1186/s13046-022-02579-9.


Comprehensive Characterization of Cachexia-Inducing Factors in Diffuse Large B-Cell Lymphoma Reveals a Molecular Subtype and a Prognosis-Related Signature.

Kuang Z, Li X, Liu R, Chen S, Tu J Front Cell Dev Biol. 2021; 9:648856.

PMID: 34079795 PMC: 8166255. DOI: 10.3389/fcell.2021.648856.


References
1.
Hou J, Schindler U, Henzel W, Ho T, Brasseur M, McKnight S . An interleukin-4-induced transcription factor: IL-4 Stat. Science. 1994; 265(5179):1701-6. DOI: 10.1126/science.8085155. View

2.
Meloche S, Pouyssegur J . The ERK1/2 mitogen-activated protein kinase pathway as a master regulator of the G1- to S-phase transition. Oncogene. 2007; 26(22):3227-39. DOI: 10.1038/sj.onc.1210414. View

3.
Mottok A, Renne C, Willenbrock K, Hansmann M, Brauninger A . Somatic hypermutation of SOCS1 in lymphocyte-predominant Hodgkin lymphoma is accompanied by high JAK2 expression and activation of STAT6. Blood. 2007; 110(9):3387-90. DOI: 10.1182/blood-2007-03-082511. View

4.
Dave S, Wright G, Tan B, Rosenwald A, Gascoyne R, Chan W . Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med. 2004; 351(21):2159-69. DOI: 10.1056/NEJMoa041869. View

5.
Rothman N, Skibola C, Wang S, Morgan G, Lan Q, Smith M . Genetic variation in TNF and IL10 and risk of non-Hodgkin lymphoma: a report from the InterLymph Consortium. Lancet Oncol. 2006; 7(1):27-38. DOI: 10.1016/S1470-2045(05)70434-4. View